BHCM
CABA icon

Brevan Howard Capital Management’s Cabaletta Bio CABA Stock Holding History

Brevan Howard Capital Management’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-149,721
Closed -$403K – 2121
2026
Q1 		$403K Buy
+149,721
New +$416K ﹤0.01% 1432

Other funds holding CABA

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Brevan Howard Capital Management's CABA Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Cabaletta Bio (CABA) in Q2 2026, closing a stake of 149,721 shares — an estimated $403K sold.

Brevan Howard Capital Management first reported a position in CABA in Q1 2026 and held it in 1 quarter. The position peaked at $403K in Q1 2026. 140 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

  • Brevan Howard Capital Management reported no remaining Cabaletta Bio position as of Q2 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 149,721 Cabaletta Bio shares in Q2 2026, an estimated $403K.
  • Brevan Howard Capital Management first reported a position in Cabaletta Bio in Q1 2026 and held it in 1 quarter.
  • Brevan Howard Capital Management's Cabaletta Bio position peaked at $403K in Q1 2026.
  • 140 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.